Your AI-Trained Oncology Knowledge Connection!

Advancements in Treatment Management Strategies for EGFR-Mutated NSCLC: Insights from Experts at The University of California Irvine : Episode 5

Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

October 23, 2023

By Misako Nagasaka, MD, PhD
Kristen Neumann, DNP, FNP-C

Opinion

Video

Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.

EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP: 9.EGFR Mutations in Patients With NSCLC

EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment

EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

4 experts in this video

A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.

4 experts in this video

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.